Biotech Acquisition Net Income

The latest net income for BIOT is $13M as of September 2022. That compares with $-2.1M in the prior-year period — up 723.9% year over year. That is below the sector sector average of $87M. Investors often review this figure alongside Biotech Acquisition's historical trend and sector peers before judging valuation or financial health.

Over the past year, BIOT's net income moved from $-2.1M to $13M — a 723.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Biotech Acquisition's operating scale or balance-sheet position.

Against its sector companies, BIOT currently prints $13M for net income, while the sector average sits near $87M. That is roughly 84.7% below the sector mean. Large gaps often invite a closer look at Biotech Acquisition's growth, margins, and balance sheet.

A net income figure of $13M for BIOT is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $87M. Explore the charts below for those layers of context.

After noting BIOT's net income ($13M), review year-over-year change from $-2.1M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.